UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Chordoma
Schwannoma (grade 1)
Craniopharyngioma
Oligodendroglioma
Meningioma
Pituitary Tumor
This observational study will collect data to better understand our patient population and their behavior around cannabis, as well as clinical outcomes that might be linked to the consumption of cannabis.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
This observational study will evaluate an assay using a patient’s own biopsy or resected tumor tissue to assess tissue response to various therapeutic agents.
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma (grade IV)
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Medulloblastoma
Ependymoma
This phase I clinical trial will study a novel drug called ALRN-6924 for treating children and young adults with recurrent or refractory solid tumors, brain tumors, lymphoma or leukemia.
Conditions
Glioma
Glioblastoma (grade IV)
This is a phase I/II trial that aims to to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the blood-brain barrier increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary
This phase I/II clinical trial will evaluate REGN2810 (also called cemiplimab) in combination with radiation therapy as a treatment for pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), ne
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Medulloblastoma
Oligodendroglioma
Pilocytic astrocytoma (grade I)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Brainstem Glioma
Diffuse Midline Glioma
Pineal Region Tumors
This phase II clinical trial tests the use of a precision medicine approach in treating pediatric patients with recurrent solid tumors, including central nervous system tumors.
Conditions
Glioma
Glioblastoma (grade IV)
This is a phase 1/2a study to assess the safety, dose-limiting toxicities, recommended Phase 2 schedule, and preliminary efficacy of aminolevulinic acid sonodynamic therapy in patients with recurrent or progressive GBM.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.
Conditions
Glioblastoma (grade IV)
Summary
This is a prospective, randomized, placebo-controlled, multi-center study of patients with newly diagnosed glioblastoma to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide given together with locally administered sargramostim plus adjuvant oral temozolomide (Arm A) versus
Conditions
Glioma
Glioblastoma (grade IV)
The FRONTIER Study is a prospective, interventional, single-arm, multi-center study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Conditions
Glioma
Glioblastoma (grade IV)
This phase II/III clinical trial is a response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM.